Multi-center phase II/III randomized controlled clinical trial using TNFerade combined with chemoradiation in patients with locally advanced pancreatic cancer (LAPC)

被引：0
|
作者：
Posner, M.
Chang, K. J.
Rosemurgy, A.
Stephenson, J.
Khan, M.
Reid, T.
Fisher, W. E.
Waxman, I.
Von Hoff, D.
Hecht, R., Jr.
机构：
[1] Univ Chicago Hosp, Chicago, IL 60637 USA
[2] Univ Calif Irvine, Orange, CA 92668 USA
[3] Univ S Florida, Tampa, FL USA
[4] Canc Ctr Carolinas, Greenville, SC USA
[5] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA
[6] Univ Calif San Diego, La Jolla, CA 92093 USA
[7] Michael E DeBakey Dept Surg, Houston, TX USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Translat Genom Res Inst, Phoenix, AZ USA
[10] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4518
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Friess, Helmut
    Langrehr, Jan M.
    Oettle, Helmut
    Raedle, Jochen
    Niedergethmann, Marco
    Dittrich, Christian
    Hossfeld, Dieter K.
    Stoeger, Herbert
    Neyns, Bart
    Herzog, Peter
    Piedbois, Pascal
    Dobrowolski, Frank
    Scheithauer, Werner
    Hawkins, Robert
    Katz, Frieder
    Balcke, Peter
    Vermorken, Jan
    van Belle, Simon
    Davidson, Neville
    Esteve, Albert Abad
    Castellano, Daniel
    Kleeff, Joerg
    Tempia-Caliera, Adrien A.
    Kovar, Andreas
    Nippgen, Johannes
    BMC CANCER, 2006, 6 (1)
  • [32] A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Helmut Friess
    Jan M Langrehr
    Helmut Oettle
    Jochen Raedle
    Marco Niedergethmann
    Christian Dittrich
    Dieter K Hossfeld
    Herbert Stöger
    Bart Neyns
    Peter Herzog
    Pascal Piedbois
    Frank Dobrowolski
    Werner Scheithauer
    Robert Hawkins
    Frieder Katz
    Peter Balcke
    Jan Vermorken
    Simon van Belle
    Neville Davidson
    Albert Abad Esteve
    Daniel Castellano
    Jörg Kleeff
    Adrien A Tempia-Caliera
    Andreas Kovar
    Johannes Nippgen
    BMC Cancer, 6
  • [33] Expression of Indoleamine 2,3-dioxygenase in erlotinib-treated patients with advanced pancreatic cancer: Translational results from a multi-center, randomized phase III trial
    Kruger, S.
    Ormanns, S.
    Roesgen, V.
    Legenstein, M.
    Haas, M.
    Westphalen, C. B.
    Duewell, P.
    Schnurr, M.
    Kirchner, T.
    von Bergwelt-Baildon, M.
    Heinemann, V.
    Boeck, S.
    EUROPEAN JOURNAL OF CANCER, 2019, 110 : S16 - S16
  • [34] Chemoradiation with or without nimotuzumab in locally advanced esophageal cancer (LAEC): A randomized phase II study (NICE trial).
    Castro, Gilberto
    Skare, Nils G.
    Andrade, Carlos J. C.
    Segalla, J. G. M.
    De Azevedo, Sergio Jobim
    Silva, Ismael D. C. G.
    Maluf Filho, Fauze
    Del Grossi Neusquen, Lucienne Pereira
    de Oliveira Berto, Cassiano Ricardo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial
    de Arruda, Fernanda Nunes
    da Costa, Samantha
    Bonadio, Renata
    Dornellas, Abraao
    Pereira, Daniela
    de Bock, Geertruida H.
    Estevez Diz, Maria Del Pilar
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (06) : 749 - 756
  • [37] A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study
    Hulshof, Maarten C. C. M.
    Geijsen, Debby
    Rozema, Tom
    Oppedijk, Vera
    Buijsen, Jeroen
    Neelis, Karen J.
    Nuyttens, Joost
    Van Der Sangen, Maurice
    Jeene, Paul
    Reinders, Janny
    Henegouwen, Mark I. van Berge
    van Hooft, Jeanin E.
    Van Laarhoven, Hanneke W. M.
    Van Der Gaast, Ate
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [38] A randomized phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial
    Cormack, Mary Mc
    Rincon, Dolores Gallardo
    Eminowicz, Gemma
    Diez, Patricia
    Farrelly, Laura
    Kent, Christopher
    Hudson, Emma
    Panades, Miguel
    Mathew, Tony
    Anand, Anjana
    Persic, Mojca
    Forrest, Jennifer
    Bhana, Rajanee
    Reed, Nicholas
    Drake, Anne
    Stobart, Hilary
    Mukhopadhyay, Asima
    Hacker, Anne-Marie
    Hackshaw, Allan
    Ledermann, Jonathan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A1 - A2
  • [39] TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC)
    Guo, Xi
    Zhou, Yuhong
    Ji, Yuan
    Lou, Wenhui
    Wu, Lili
    Wang, Wenquan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer
    Heinemann, V.
    Ebert, M. P.
    Pinter, T.
    Bevan, P.
    Neville, N. G.
    Mala, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345